Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01217008 · ClinicalTrials.gov registry record · Phase 1
Safety Study of GRNOPC1 in Spinal Cord Injury
A Phase 1 study, sponsored by Lineage Cell Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01217008 is a Phase 1 study that has completed, run by Lineage Cell Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT01217008, a Phase 1 study, has completed, sponsored by Lineage Cell Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).
Interventions
- BIOLOGICAL GRNOPC1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01217008
The ClinicalTrials.gov registry entry for NCT01217008 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lineage Cell Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GRNOPC1 is the first listed.
NCT01217008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01217008 about?
NCT01217008 is a clinical study titled "Safety Study of GRNOPC1 in Spinal Cord Injury". The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).
What is the current status of trial NCT01217008?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-10. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01217008?
The interventions under investigation include: GRNOPC1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01217008?
This trial is sponsored by Lineage Cell Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.